Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19"

Massimo Iavarone, Roberta D'Ambrosio, Pietro Lampertico, CirCoV study group, M Iavarone, R D'Ambrosio, A Rimondi, P Lampertico, A Soria, P Bonfanti, M Triolo, S Fagiuoli, N Pugliese, A Aghemo, P Del Poggio, G Perricone, L S Belli, S Massironi, M Lucà, P Invernizzi, A Spinetti, C Carriero, E Buscarini, M Pedaci, M Viganò, M G Rumi, Massimo Iavarone, Roberta D'Ambrosio, Pietro Lampertico, CirCoV study group, M Iavarone, R D'Ambrosio, A Rimondi, P Lampertico, A Soria, P Bonfanti, M Triolo, S Fagiuoli, N Pugliese, A Aghemo, P Del Poggio, G Perricone, L S Belli, S Massironi, M Lucà, P Invernizzi, A Spinetti, C Carriero, E Buscarini, M Pedaci, M Viganò, M G Rumi

No abstract available

Keywords: HBV; HCV; Hepatitis; Hepatocellular carcinoma; Liver transplantation; SARS-CoV-2.

Conflict of interest statement

Conflict of interest Massimo Iavarone: Speaking/Teaching, consultant and advisory board for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, EISAI; Roberta D'Ambrosio: teaching and speaking for AbbVie, Gilead, MSD; Advisory Board for AbbVie, MSD, Research Grant from Gilead; Pietro Lampertico: Advisory Board/Speaker Bureau for BMS, Roche, Gilead, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger. Please refer to the accompanying ICMJE disclosure forms for further details.

References

    1. Iavarone M., D'Ambrosio R., Soria A., Triolo M., Pugliese N., Del Poggio P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 doi: 10.1016/j.jhep.2020.06.001.
    1. Bajaj J.S., Garcia-Tsao G., Biggins S.W., Kamath P.S., Wong F., McGeorge S. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared to cirrhosis alone and COVID-19 alone: a multi-center matched cohort. Gut. 2020 doi: 10.1136/gutjnl-2020-322118.
    1. Moon A.M., Webb G.J., Aloman C., Armstrong M.J., Cargill T., Dhanasekaran R. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020;73(3):705–708.
    1. Boettler T., Newsome P.N., Mondelli M.U., Maticic M., Cordero E., Cornberg M. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113.
    1. Iavarone M., Sangiovanni A., Carrafiello G., Rossi G., Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol. 2020;31(8):1084–1085.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir